Intensity Therapeutics, Inc. (INTS)
- Previous Close
4.8400 - Open
4.8100 - Bid --
- Ask --
- Day's Range
4.8100 - 4.9400 - 52 Week Range
2.0100 - 11.4400 - Volume
7,991 - Avg. Volume
32,080 - Market Cap (intraday)
67.737M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
www.intensitytherapeutics.comRecent News: INTS
Performance Overview: INTS
Trailing total returns as of 5/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INTS
Valuation Measures
Market Cap
67.74M
Enterprise Value
57.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
6.97
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.58%
Return on Equity (ttm)
-261.36%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.86M
Diluted EPS (ttm)
-1.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
14.78M
Total Debt/Equity (mrq)
1.20%
Levered Free Cash Flow (ttm)
-2.77M